The presentation will begin with an overview of the clinical characteristics of high-risk multiple myeloma, highlighting the challenges associated with its treatment. It will discuss the key Phase 3 clinical trial data of anti-CD38 therapies, evaluating their efficacy and safety for the high-risk cytogenetic population. The lecture will also include the latest scientific updates on therapies in the upfront setting for newly diagnosed MM patients, based on emerging data from ongoing clinical trials.